封面
市場調查報告書
商品編碼
1138396

2022-2029 年3D打印藥品全球市場

Global 3D Printed Drugs Market - 2022-2029

出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

全球 3D 打印藥品市場的增長受到多個因素的推動,例如全球醫療事故增多、對更便宜的藥物和平板電腦的需求增加以及 3D 打印在醫療行業的適用性增加。這是由於人們越來越意識到 3D 打印藥物的好處,例如即時溶解。 3D 打印藥物更容易吞嚥。預計這些藥物在預測期內的需求將增長,因為它們可以根據每位患者的要求進行定制,並且比批量生產的藥物提供更好的幫助。

3D 打印技術的進步和投資的增加預計將成為預測期內的驅動力。

2020 年 10 月,中國四川大學和廈門大學的研究人員開發了一種 3D 打印的自粘繃帶,可以輸送神經癒合藥物。研究小組製作的紗布由兩層水凝膠層組成,兩層水凝膠層可通過點擊激活,內部部分可裝載再生藥物。當包裹在神經損傷部位時,藥物會被釋放以刺激周圍神經系統 (PNS) 中的神經膠質細胞生長。研究人員希望,在未來,新的 3D 打印敷料可以幫助醫生,醫生廣泛用於神經切除術等神經修復手術。此外,增加投資以加強研究活動以開發高效 3D 打印藥物預計將在預測期內推動市場增長。例如,2020 年 12 月,中國 3D 打印技術初創公司 Triastek 在 A 輪融資中籌集了 1500 萬美元,用於加速 3D 打印藥物的研發。基金管理公司 Dalton Venture 領投了本輪融資,其他共同投資者包括上海東富龍科技、科技董事長鄭曉東和雲啟合夥人。 Triastek 計劃利用這筆資金研發 3D 打印藥物並建設大規模生產線,同時在中國和美國進行註冊。由於這些原因,預計它將成為預測期內市場的驅動力。

約束

但是,預計 3D 打印藥物的副作用和缺乏政府監管將阻礙市場增長。此外,一些醜聞和對在線存儲數據的黑客攻擊可能使患者越來越不願意透露他們的醫療信息。此外,對藍圖的虛假陳述和輸入不正確的描述也是市場面臨的主要挑戰,因為需要創建患者的 3D 藍圖、他們的劑量和病史來製備 3D 打印藥物。

行業分析

3D 打印藥品市場根據各種行業因素對市場進行深入分析,包括未滿足的需求、定價分析、供應鏈分析和監管分析。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按藥物劃分的市場細分
  • 按技術劃分的市場細分
  • 最終用戶的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 3D 打印在醫療行業的使用率不斷提高
      • 越來越多地採用個性化藥物
    • 限制因素
      • 使用 3D 打印機製造的藥物的副作用
    • 商機
    • 影響分析

第五章行業分析

  • 波特五力分析
  • 監管分析
  • 定價分析
  • 供應鏈分析
  • 產品創新
  • 未滿足的需求

第六章藥物

  • Spritum
  • 其他

第 7 章按技術分類

    • 噴墨打印
    • 融合增材製造 (FDM)
    • 立體光刻 (SLA)
    • 其他

第 8 章最終用戶

    • 醫院
    • 診所
    • 研究所
    • 其他

第 9 章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 10 章競爭格局

  • 競爭場景
  • 市場情況/份額分析
  • 併購分析

第 11 章公司簡介

  • Aprecia Pharmaceuticals
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • GlaxoSmithKline Plc.
  • Hewlett Packard Caribe, BV, LLC
  • FabRx Ltd. (*LIST NOT EXHAUSTIVE)

第12章 DataM

簡介目錄
Product Code: DMPH1495

Market Overview

3D Printed Drugs Market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 8.10% during the forecast period (2022-2029)

3D printed drugs are drugs manufactured by solidifying layers of materials to form a definite 3D structure. The adaptability of 3D printing is also applied for the precise and unique dosing of medicines to present more efficient drug administration. 3D printing is expected to be an efficient method to enhance the application of several controlled drug release mechanisms during the forecast period.

Market Dynamics

The global 3D printed drugs market growth is driven by several factors such as rising healthcare disorders globally and rising demand for cheaper drugs or pills, and increasing adaptability of 3D printing in the medical industries. With rising awareness of the advantages of 3D printed drugs, such as their instantaneous solubility. 3D printed drugs are extremely easy to swallow. As these drugs can be customized according to the requirement of every patient, assisting way better than batch-produced drugs, the demand is expected to grow over the forecast period.

Growing advancements in 3D Printing Technology and rising investments are expected to drive in the forecast period.

In October 2020, researchers from China's Sichuan University and Xiamen University developed 3D printed self-adhesive bandages capable of delivering nerve-healing drugs. The team's fabricated gauze comprises two click-activated hydrogel layers and an inner section that can be loaded with regenerative medicine. Once wrapped around the site of an injured nerve, the device releases the medication in a way that encourages the growth of glial cells in the Peripheral Nervous System (PNS). In the future, the scientists believe that their novel 3D printed dressing design could assist doctors carrying out widely-used nerve repair operations such as neurorrhaphy. Moreover, the rising investments to increase the research activities for developing highly efficient 3D printed drugs are expected to boost the market's growth during the forecast period. For instance, in December 2020, Triastek, a Chinese 3D printing technology startup, raised $15 million in Series A funding to accelerate the research and development of its 3D-printed drugs. The fund management company Dalton Venture led the funding round, while other co-investors included Shangahi Tofflon Science, Technology Chairman Zheng Xiaodong, and Yunqi Partners. Triastek will use the funds for the research and development of its 3D printed medicines alongside registration applications in China and the US and in constructing a large-scale production line. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

However, the adverse effects of 3d printed drugs' lack of government regulations are expected to hinder the market's growth. Also, several scandals and hacking of data stored online could make patients increasingly reluctant to disclose their medical information. In addition, mislabelling blueprints and inputting wrong descriptions is also a big challenge for the market as a 3D blueprint must be made of the patient, their dosage, and medical history to prepare a 3D printed drug.

Industry Analysis

The 3D printed drugs market provides in-depth analysis of the market based on various industry factors such as unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.

Segment Analysis

Fused Deposition Modelling (FDM) segment is expected to hold the largest market share in the 3D printed drugs market.

The fused deposition modelling (FDM) segment accounted for the largest market share in 2021. The segment benefits because FDM is a production method used for fabrication, production applications, and mechanical system modeling. The technique produces a tissue scaffold using a layer-by-layer thermoplastic polymer by the melt extrusion method. It is also known as material extrusion and is currently the most popular AM technology on the market. It fabricates durable components made of high-strength thermoplastics such as ULTEM, polycarbonate, polyphenylsulfone, polylactic acid, and acrylonitrile butadiene styrene. The FDM technique is one of the most widespread in drug 3D printing. Filaments loaded with medicines can be used for the manufacture of the pills. Fused Deposition Modeling (FDM) can make combinations of multiple drugs (polyps) and sustained or delayed-release tablets. The unique design of the FDM printer allows it to make gantry rails longer and expand the build area's size. This mechanism allows the designer to scale any print as wishes easily. The cost-to-size ratio is an added advantage for the user of the FDM printer. However, the FDM printer might be the best option for personal use, but when it comes to mass production, it is advised against using it.

Moreover, FDM printers are compatible with a wide variety of thermoplastic polymers like PLA and ABS and Polycarbonates such as PET, PS, ASA, PVA, Nylon, and even composite filaments based on metal, stone, wood, and more. These composites often offer interesting mechanical properties such as being conductive, bio-compatible, or heat resistant. These materials vary in price, with 1kg of PLA filament retailing at around $30/£20. FabRx's fused deposition modeling (FDM) 3D printers melt a mixture of drugs and excipients through a nozzle onto a build plate to construct a dosage form layer-by-layer. FabRx manufactures its filaments, comprised of pharmaceutical-grade materials, which can be drug-loaded to create sustained or delayed-release tablets and multi-drug combinations (polypills). FDM 3D printers range in price greatly. The cheapest, self-assemble RepRap types start at €300. This price costs €2,500 for medium-range models and nearly €10,000 for professional-level machines. The main players in this market include the original manufacturer Stratasys, brands like MakerBot (acquired by Stratasys in 2013), Ultimaker and Prusa. Thus, from the above statements, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North American region is expected to hold the largest market share in the global 3D printed drugs market.

North America has the largest share in the global 3D printed drugs market. The US is the only country that has approved the first 3D drug called Spritam (levetiracetam). The first 3D-printed drug to receive approval from the US Food and Drug Administration (FDA) is now being shipped to pharmacies. The company is also working on at least three other 3D-printed drugs it expects to bring to market eventually. Levetiracetam, the generic name for Spritam, has been available for treating seizures for 15 years. But the new brand Spritam is the first to use the proprietary 3D-printing process to create a more dissolvable pill. The surge in demand for instantaneous soluble drugs that can disperse easily in the mouth is the major factor driving the country's market growth.

Additionally, many state of the art universities collaborate with 3D drug manufacturing companies to research and develop new pharmaceuticals. For instance, in 2020, Aprecia Pharmaceuticals LLC partnered with Purdue University's College of Pharmacy to advance the technology and science of 3D pharmaceutical printing. Through this partnership, the companies will focus on developing future 3D-printed pharmaceutical equipment and medications. Thus, from the above statements, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the 3D printed drugs market are Aprecia Pharmaceuticals, GlaxoSmithKline Plc., Hewlett Packard Caribe, BV, LLC, FabRx Ltd.

GlaxoSmithKline PLC:

GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat acute and chronic diseases. The Vaccines business provides vaccines for people of all ages, from babies and adolescents to adults and older people. It has a portfolio of medicines for respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty Products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, and older people and travel vaccines

Product Portfolio:

Ropinirole: The piezo-activated inkjetting to 3D print ropinirole hydrochloride. The tablets produced consist of a cross-linked poly(ethylene glycol diacrylate) (PEGDA) hydrogel matrix containing the drug, photoinitiated in a low oxygen environment using an aqueous solution of Irgacure 2959.

The global 3D printed drugs market report would provide an access to an approx. 45+market data table, 40+figures

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Drug
  • 3.2. Market snippet by Technology
  • 3.3. Market Snippet by End-User
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising usage of 3D printing in the medical industries
      • 4.1.1.2. Increasing adoption of personalized drugs
    • 4.1.2. Restraints
      • 4.1.2.1. Adverse effects of 3D printed drugs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Regulatory Analysis
  • 5.3. Pricing Analysis
  • 5.4. Supply Chain Analysis
  • 5.5. Product Innovations
  • 5.6. Unmet Needs

6. By Drug

  • 6.1. Introduction
  • 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Segment
  • 6.3. Market Attractiveness Index, By Drug Segment
    • 6.3.1. Spritam *
      • 6.3.1.1. Introduction
      • 6.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 6.3.2. Others

7. By Technology

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology Segment
  • 7.3. Market Attractiveness Index, By Technology Segment
    • 7.3.1.
      • 7.3.1.1. Inkjet printing*
      • 7.3.1.1.1. Introduction
      • 7.3.1.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
      • 7.3.1.2. Fused deposition modelling (FDM)
      • 7.3.1.3. Stereolithography (SLA)
      • 7.3.1.4. Others

8. By End-User

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User Segment
  • 8.3. Market Attractiveness Index, By End-User Segment
    • 8.3.1.
      • 8.3.1.1. Hospitals*
      • 8.3.1.1.1. Introduction
      • 8.3.1.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
      • 8.3.1.2. Clinics
      • 8.3.1.3. Research Laboratories
      • 8.3.1.4. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Italy
      • 9.3.6.5. Spain
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. Australia
      • 9.5.6.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Aprecia Pharmaceuticals*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. GlaxoSmithKline Plc.
  • 11.3. Hewlett Packard Caribe, BV, LLC
  • 11.4. FabRx Ltd. (*LIST NOT EXHAUSTIVE)

12. DataM Intelligence

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us